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ABSTRACT 31 
Objective: To examine functional performance differences using kinematic and kinetic 32 
analysis between participants with and without knee osteoarthritis (OA) to determine 33 
which outcomes best characterize persons with and without knee OA. 34 
Methods: Participants with unilateral moderate knee OA (Kellgren-Lawrence grades 2 35 
or 3) and controls without knee pain were matched for age, gender, and body mass 36 
index. Primary outcomes included temporal parameters, joint rotations and moments, 37 
and ground reaction forces assessed via 3D motion capture during walking and 38 
ascending/descending stairs. Secondary outcomes included timed functional activities 39 
(sit to stand; tying shoe laces), 48-hour lower limb activity monitoring, and patient-40 
reported outcome measures (KOOS, WOMAC Osteoarthritis Index, EQ-5D). 41 
Results: Eight matched pairs were analyzed. Compared with controls, OA participants 42 
exhibited significant reductions in peak frontal hip and sagittal knee moments, and 43 
decreased peak anterior ground reaction force with the affected limb while walking. 44 
Ascending stairs, OA participants had slower speed, fewer strides per minute, longer 45 
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cycle and stance times, and increased trunk range of motion (ROM) in assessments of 46 
both limbs; longer swing time and reduced ankle ROM in the affected limb; and 47 
increased knee frontal ROM in the unaffected limb. Descending stairs, OA participants 48 
had fewer strides per minute and decreased trunk transverse ROM in assessments of 49 
both limbs; increased knee frontal ROM in the affected limb; and longer strides, shorter 50 
stance and cycle times, increased trunk sagittal and decreased knee transverse ROMs 51 
in the unaffected limbs versus controls. Compared with controls, OA participants had 52 
slower walking cadence (120–130 vs 100–110 steps/minute, respectively), took 53 
significantly longer on timed functional measures, and had significantly worse scores in 54 
patient-reported outcomes.  55 
Conclusions: Several objective and patient-reported measures examined in this study 56 
could potentially be considered as outcomes in pharmacologic or physical therapy OA 57 
trials. 58 
 59 
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INTRODUCTION 63 
Knee osteoarthritis (OA), a major cause of disability worldwide,1 adversely affects 64 
health-related quality of life2 and causes significant morbidity.3 When conservative 65 
measures fail, patients often experience years of pain, affecting activities of daily living  66 
before proceeding, if eligible, to surgical intervention such as total knee arthroplasty.4 67 
 68 
Numerous objective outcomes are used in OA studies, but it remains unclear which best 69 
characterize OA-related changes.5 A systematic review found evidence gaps with most 70 
measures; the 15.2-meter fast-paced walk test, 30-second chair-stand test, and timed 71 
up-and-go test provided the most effective indicators of knee OA.6 An expert consensus 72 
report has recommended the 40-meter fast-paced walk test, 30-second chair-stand test, 73 
stair-climb test, timed up-and-go test, and 6-minute walk test.7 74 
 75 
Furthermore, it remains unclear which outcome measures best differentiate persons 76 
with and without OA when age and body mass index (BMI) are matched, as knee OA 77 
incidence increases with age and BMI,8,9 and obesity is associated with increased OA 78 
progression.10 79 
 80 
This study aimed to identify differences in physical function and performance of 81 
essential activities between patients with moderate knee OA and matched controls 82 
without knee symptoms. We hypothesized that participants with OA would demonstrate 83 
poorer results in all kinematic, kinetic, timed functional, and patient-reported measures 84 
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compared with healthy controls, and that the results could potentially be used to guide 85 
pharmacologic and non-pharmacologic intervention studies for moderate knee OA. 86 
 87 
METHODS 88 
Study Design and Procedures 89 
This observational, non-interventional study, conducted at the School of Engineering, 90 
Cardiff University, Cardiff, Wales, UK, compared people with unilateral (medial or lateral 91 
compartment) moderate knee OA (Kellgren-Lawrence OA classification grade 2 or 3), 92 
with a control group without knee or lower limb symptoms matched for age, gender, and 93 
BMI. At visit 1, participants provided demographic and medical history information and 94 
an ActivPAL™ activity monitor (PALtechnologies Ltd, Glasgow, Scotland, UK) was 95 
attached to the right thigh (for consistency, as the ActivPAL is a measure of general 96 
activity) and worn for 48 hours. ActivPAL registers activity utilizing acceleration and 97 
inclination logging technology and algorithms log walking speed and cadence.  98 
 99 
They also completed validated subjective questionnaires: Knee Injury and Osteoarthritis 100 
Outcome Score (KOOS),11,12 European Quality of Life–5 Dimensions (EQ-5D),13-16 and 101 
Western Ontario McMaster Universities (WOMAC) Osteoarthritis Index.17 The 102 
researchers checked that all questionnaires were completed appropriately.  103 
 104 
Two days after visit 1, investigators phoned participants with OA to assess pain severity 105 
using a numeric pain rating scale from 0 (no pain) to 10 (maximum/extreme pain). 106 
Participants with ratings ≥4 and ≤7 returned to the laboratory that day for assessment. 107 
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These thresholds were used to ensure that the assessments were made while patients 108 
were experiencing pain symptoms. A level of ≤7 was used as a maximum cut-off 109 
because participants with higher scores could potentially be adversely affected (ie, 110 
marked increase in pain) by walking and stair-climbing activities. Controls were 111 
assessed at the laboratory approximately 48 hours after ActivPAL application. 112 
 113 
At visit 2, participants were evaluated using 3D motion analysis with a full-body modified 114 
Helen Hayes marker set18 extended with thigh- and shank-fixed clusters, as well as 115 
additional foot and pelvis markers; iliac crest markers were used to better define the hip 116 
during stair trials. Nine Oqus infra-red cameras (Qualisys, Gothenburg, Sweden) 117 
captured 3D marker motion at 120 Hz. Force data were collected at 1080 Hz from 4 118 
force plates (Bertec Corporation, Columbus, Ohio, USA) embedded in the laboratory 119 
floor. Participants were recorded while walking 6 times across the level laboratory floor 120 
(over the force plates) and while ascending and descending a 4-step staircase19 6 times 121 
(3 trials leading with each leg). Custom software (Visual3D, C-Motion, Inc, Germantown, 122 
Maryland, USA) was used to scale a model to the standing position for each participant 123 
and apply this model to the movement data. Reports containing temporal parameters, 124 
joint rotations, external joint moments (rotation forces acting around the joint), and 125 
ground reaction forces were produced for each participant. Participants also completed 126 
timed activities of daily living: sit to stand, stand to sit, tying shoelaces, and 10-meter 127 
walk. 128 
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 129 
Study Population 130 
Patients with knee OA were recruited from Cardiff and Vale University Hospital Board 131 
Physiotherapy Department outpatient clinics, University Hospital of Wales, Cardiff, 132 
Wales, UK. Controls were recruited from Cardiff and the surrounding region via poster 133 
and electronic advertising forums for staff at Cardiff University. Volunteers contacted 134 
researchers by e-mail or telephone and were assessed for eligibility. Recruitment began 135 
January 2, 2015 and data collection ended on February 26, 2016. Recruitment 136 
continued through March 31, 2016 in an unsuccessful attempt to identify the final 2 137 
matched control subjects. 138 
 139 
Eligible participants were 45 to 65 years and able to comply with instructions and study 140 
procedures. OA participants had to have a 6-month history of moderate unilateral 141 
(medial or lateral) OA in either knee confirmed by radiographic evidence of joint space 142 
narrowing (grade 2 or 3 based on Kellgren-Lawrence OA classification) and pain 143 
intensity of ≥4 and ≤7 on a scale of 0 (no pain) to 10 (maximum/extreme pain). Verbal 144 
checks were made to ensure OA participants had no current soft tissue injuries to the 145 
lower limbs. Controls had to have good general health, normal strength, and full range 146 
of motion (ROM) of the lower extremities, with no history of knee OA, knee instability, 147 
major lower extremity joint surgery, or current soft tissue injuries to the lower limbs and 148 
no neurologic deficits.  149 
 150 
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The protocol initially required controls to be matched to OA participants within ±2 years 151 
of age and ±5 kg/m2 for BMI, as well as gender. Due to recruiting challenges (BMI was 152 
usually too low among controls who matched for age), criteria were subsequently 153 
changed to ±5 years for age and ±5 kg/m2 for BMI. 154 
 155 
Key exclusion criteria for both groups included adhesive tape allergy; neurologic or 156 
balance disorder; recent (≤2 years) alcohol or other substance abuse; and history of 157 
cerebrovascular accident, head injury, or systemic inflammatory arthritis.  158 
 159 
Participants had to discontinue oral or topical analgesics during the 48 hours between 160 
visits 1 and 2. Up to 1000 mg paracetamol 4 times daily was permitted as rescue 161 
medication, in accordance with European League Against Rheumatism (EULAR) 162 
recommendations for knee, hip, and hand OA.20 However, participants had to have at 163 
least 2 consecutive days without pain medication before visit 2. 164 
 165 
Outcomes 166 
Primary endpoints were 3D kinematic and kinetic data from the motion analysis during 167 
level walking and stair ascent and descent, and included temporal-spatial parameters, 168 
joint rotations, joint moments, and ground reaction forces. Temporal-spatial measures 169 
consisted of walking speed (m/s), stride width/length (m), cycle time (s), step length (m), 170 
step time (s), stance time (s), swing time (s), and strides per minute. Kinematic joint 171 
range of motion (ROM; in degrees) was determined at the hip, knee, ankle, pelvis, and 172 
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trunk, and defined through transformation from tracking markers to the pose of each 173 
segment of the biomechanical model.  174 
 175 
Cardan sequences of joint angles (X, Y, and Z, representing flexion/extension, 176 
abduction/adduction, and axial rotation, respectively, and equivalent to the “joint 177 
coordinate system”21,22) were used to compute ankle, knee, and hip kinematics, 178 
following International Society of Biomechanics recommendations.23 Trunk rotations 179 
were also calculated using Cardan sequence X-Y-Z, whereas a Z-Y-X (axial rotation, 180 
obliquity, tilt) description was used to compute pelvic rotations, following 181 
recommendations of Baker et al.24 Inverse dynamics analysis was applied to kinematics 182 
of the biomechanical model and location, magnitude, and direction of ground reaction 183 
forces acting on the foot. This process computed external moments acting about the 184 
ankle, knee, and hip joints, which were resolved to distal joint segments. 3D kinetic 185 
measures consisted of XYZ joint moments at stance phase for hip, knee, and ankle 186 
(percentage body weight x height) and XYZ power at stance phase for hip, knee, and 187 
ankle (w/kg). XYZ ground reaction forces (medial-lateral, anterior-posterior, and vertical) 188 
were normalized to body weight and XY center of pressure of ground reaction force 189 
during stance phase (M), normalized to foot width and length. 190 
 191 
Secondary endpoints included KOOS,11,12 EQ-5D,13-16 and WOMAC Osteoarthritis 192 
Index17 scores, walking performance based on ActivPAL, and performance on the timed 193 
activities of daily living. ActivPAL measures were number of steps taken, cadence 194 
(steps/minute), time (minutes) spent lying/sitting and standing, number of stepping 195 
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events, total number of upright events, and total number of seated events. Safety 196 
outcomes included adverse events (AEs), consisting of any untoward medical 197 
occurrence following data collection at the 2 visits, or reported in response to 198 
questioning via telephone between visits. 199 
 200 
Statistics 201 
No formal power calculation was performed for this exploratory study. The protocol 202 
called for 10 OA participants and 10 matched controls as this was deemed sufficient to 203 
answer the research question and objectives. 204 
 205 
For the primary 3D motion analyses, only matched pairs of OA and control subjects 206 
were included. Kinematic and kinetic variables were calculated as mean ± standard 207 
deviation (SD) for each limb. After testing for normal distribution using histograms, data 208 
were deemed not to be normally distributed; therefore, the Wilcoxon signed-rank test, a 209 
paired non-parametric analysis, was used to analyze differences between OA patients 210 
and controls. For each matched pair, the affected leg of the OA participant was 211 
compared with the same leg (left/right) of the matched control; the same was done for 212 
the unaffected leg. Temporal-spatial measures were summarized by descriptive and 213 
inferential statistics. Descriptive statistics were used for patient-reported outcome 214 
questionnaires, timed functional tests, and ActivPAL results, and between-group 215 
differences (OA and controls) were analyzed by Wilcoxon signed-rank test. Data that 216 
were missing due to technical errors were excluded from the analyses.  All analyses 217 
were conducted using Statistics Package for Social Sciences (IBM US), Version 20. 218 
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 219 
RESULTS 220 
Participants 221 
Of 65 OA participants screened, 11 were recruited; of 43 healthy participants screened, 222 
8 controls were recruited. The eleventh OA subject was recruited as a replacement for a 223 
subject whose data were inadequate for processing because loose clothing had 224 
impaired marker visibility. Because we were unable to recruit 2 controls to match 2 OA 225 
patients with the highest BMIs, 3D motion analysis was performed on 8 matched pairs. 226 
Other objective analyses included 10 OA participants and 8 controls. Of the 10 OA 227 
patients, 6 had OA in the right knee, and 4 had OA in the left knee. Baseline 228 
demographics were similar for OA participants and controls (Table 1). 229 
 230 
Objective Measures of Function 231 
Level Walking 232 
3D motion analysis during level walking noted that the OA-affected limb had significantly 233 
reduced maximum frontal (adduction) hip moment (P=0.036) and sagittal (flexion) knee 234 
moment (P=0.025) compared with the corresponding limb of controls (Table 2). A 235 
significant decrease in the anteriorly directed ground reaction force during the second 236 
half of stance was found for the OA-affected limb compared with the corresponding limb 237 
of controls (mean [SD] 0.16 [0.06] vs 0.22 [0.03] percent body weight [%BW]; P=0.025).  238 
 239 
Hip, knee, ankle, and trunk ROM were not significantly different between OA 240 
participants on the affected or unaffected limb and corresponding limbs of controls, nor 241 
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were there significant differences in walking speed, stride width/length, cycle time, step 242 
length, step time, stance time, swing time, or strides per minute. 243 
 244 
Ascending and Descending Stairs 245 
There were no significant differences in ground reaction forces or joint moments of the 246 
hip, knee, and ankle in affected or unaffected limbs of OA participants and 247 
corresponding limbs of controls while ascending or descending stairs. 248 
 249 
Table 3 shows temporal data from 3D motion analysis while ascending and descending 250 
stairs. During ascent, participants with OA had slower speed and fewer strides per 251 
minute with both limbs compared with controls. OA participants had longer cycle and 252 
stance times in both limbs, and longer swing time in the affected limb, compared with 253 
controls. During descent, OA participants took fewer strides per minute with both limbs 254 
versus controls. On measurements of unaffected limbs, while descending stairs, OA 255 
participants had longer stride length, and shorter stance and cycle time than controls. 256 
 257 
Table 4 shows results for the ROM analysis while ascending and descending stairs. 258 
During ascent, knee ROM for OA-affected limbs was similar to corresponding limb in 259 
controls, but OA participants had greater frontal knee ROM in the unaffected knee 260 
versus controls. Sagittal ankle ROM was decreased in OA-affected limbs versus 261 
controls, and sagittal and transverse trunk ROM were increased in the cycles of both 262 
limbs of OA participants compared with controls while ascending stairs. Hip ROM was 263 
not different for OA participants versus controls, for the affected or unaffected side. 264 
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 265 
While descending stairs, OA participants had greater knee frontal ROM in the affected 266 
limb, and less knee transverse ROM in the unaffected limb compared with controls. 267 
Trunk sagittal ROM was increased in cycles of the unaffected side of OA participants 268 
compared with the corresponding side of controls, and trunk transverse ROM was 269 
decreased on assessments of both sides of OA participants versus controls. Hip and 270 
ankle ROM did not differ during stair descent for either limb of OA participants 271 
compared with controls. 272 
  273 
Time to Complete Functional Tests 274 
Based on ActivPAL, participants with OA had slower cadence while walking compared 275 
with controls. Descriptive data show that the most common cadence was 100 to 110 276 
steps/minute for OA participants and 120 to 130 steps/minute for controls (Figure 1). 277 
Other ActivPAL measures were not significantly different between the 2 populations. OA 278 
participants took significantly longer than controls on all timed activities (Table 5). 279 
 280 
Subjective Patient-Reported Outcomes 281 
Patient-reported outcomes surveys (KOOS, WOMAC Osteoarthritis Index, and EQ-5D) 282 
were completed by all 10 OA subjects and 7 of the 8 controls. The OA participants had 283 
significantly lower scores than controls on all domains of the KOOS and WOMAC 284 
Osteoarthritis Index (Table 6). The EQ-5D asked participants to rate their current health 285 
state on a scale from 0 (worst imaginable) to 100 (best imaginable health). The mean 286 
(standard deviation [SD]) score was 81.3 (15.1) among OA participants and 96.9 (11.7) 287 
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among controls (P=0.019). On other sections of the EQ-5D, a larger percentage of OA 288 
participants compared to controls reported having some or extreme problems with 289 
pain/discomfort, mobility, and usual activities (Figure 2).  290 
 291 
Safety 292 
There were no AEs in this non-interventional study. OA participants all tolerated the 293 
study protocol without rescue analgesics.  294 
 295 
DISCUSSION  296 
This study identified objective measures of functioning that differentiate people with and 297 
without knee OA. These results may help guide selection of outcomes for OA treatment 298 
intervention trials.  299 
 300 
With 3D motion analysis, kinetic data demonstrated significantly decreased hip frontal 301 
(adduction) moments in OA-affected limbs during level walking, which has been seen in 302 
other studies of moderate or severe OA.25 The reduced knee sagittal (flexion) moment 303 
we observed in OA participants has also been seen with increasing OA severity25 and 304 
may be a compensatory mechanism of limiting knee flexion, and therefore compressive 305 
forces in the knee, during weight acceptance. 306 
 307 
OA participants ascended stairs more slowly, spending longer time in stance and with 308 
greater swing time of the gait cycle. Reasons for this could include muscle weakness, 309 
apprehension of pain, or actual pain. However, increased stance time could indicate 310 
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longer loading time, which may increase pain. Increased joint contact forces 311 
experienced during stair ascent, compared with level walking, may exacerbate pain.26 312 
Compared with controls, OA participants had significantly decreased strides per minute 313 
on both limbs and increased stride length, and shorter cycle and stance time on the 314 
unaffected limb while descending stairs.  315 
 316 
While ascending stairs, OA participants had increased sagittal and transverse trunk 317 
ROM in cycles assessing both limbs. While descending, sagittal trunk ROM was 318 
increased during assessments of the unaffected limb, and transverse trunk ROM was 319 
decreased during assessments of both limbs. Increased lateral trunk ROM has been 320 
observed in other studies of OA,27-29 and may be another compensatory mechanism. 321 
OA participants rotated their pelvis more during stair ascent, possibly because some 322 
chose to use the handrail, which was discouraged but available for safety. The only 323 
differences in hip, knee, and ankle kinematics during ascent were a decreased ankle 324 
sagittal ROM on the affected limb, and an increased frontal knee ROM on the 325 
unaffected limb. Knee frontal ROM was increased in the affected limb during descent, 326 
which could be due to a decrease in knee stability during the single support phase on 327 
the affected leg.  328 
 329 
OA participants took fewer steps per minute while walking based on the ActivPAL and 330 
took longer to complete a timed 10-meter walk, tie shoes, and sit or stand. It could be 331 
hypothesised that anticipation of pain, actual pain, and/or joint stiffness may have 332 
contributed to slower times to complete these tasks. Results of the ActivPAL cadence 333 
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measure and timed 10-meter walk contrast with the lack of difference in walking speed 334 
and walking cycle time on 3D motion capture. Reasons for this may be because on 3D 335 
motion capture, speed is calculated within the Visual3D (C-Motion, USA) software from 336 
heel strike to heel strike for each trial and then averaged. This represents a shorter 337 
distance with potentially more variable results, subject to a larger error margin 338 
compared with the longer 10-meter walk, where differences are cumulative over the 339 
total number of gait cycles. It is also possible that cumulative fatigue and discomfort 340 
over the 1.5- to 2-hour assessment period contributed to slower walking on the timed 341 
10-meter walk, which was one of the last assessments performed. The ActivPAL data 342 
were collected over a 48-hour period of regular activity, whereas 3D motion analysis  343 
data were collected at a single time in the laboratory, making comparisons difficult. 344 
People may walk differently under laboratory conditions than when walking at their own 345 
pace, in their choice of footwear, in real-world settings. The longer period of data 346 
collection with the ActivPAL may also facilitate detection of differences. 347 
 348 
Other studies have found walking speed and sitting/standing speed to be useful 349 
performance measures for persons with OA or other knee joint diseases.6,29-31 350 
Consistent with our results, a previous study showed a slower sit-to-stand time in 351 
patients with knee OA compared with controls without OA.32 That study also found that 352 
OA patients lean forward, shifting their center of mass over their feet, while minimizing 353 
knee extension as they stand up, to improve stability as they leave the chair.32  354 
 355 
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Our study identified fewer differentiating outcomes between OA subjects and controls 356 
than previous 3D motion capture studies. One such study found moderate or severe OA 357 
to be associated with reduced speed, increased stance time and percentage, increased 358 
stride time, decreased stride length, reduced knee early stance flexion moments, 359 
increased knee mid-stance adduction moments, reduced peak hip adduction moments, 360 
and reduced late stance hip extension moments.25 Another study identified walking 361 
speed, stride length, hip and knee flexion, thorax obliquity, and knee adductor moments 362 
during early and terminal stance as objective parameters that differentiate persons with 363 
severe OA from persons without knee pathology.33 Our inclusion criteria for OA 364 
participants required that they have moderate OA (Kellgren-Lawrence grade 2 and 3), 365 
which may differ from other studies; also there may be differences in the type of data 366 
analyses performed and procedures used.  367 
 368 
Differences in patient-reported outcomes were not unexpected given differences in 369 
inclusion/exclusion criteria for the 2 groups and the well-established effects of OA on 370 
these outcomes.2,25,34 The findings regarding patient-reported outcomes are also 371 
consistent with previous reports about the impact of OA on disability and quality of 372 
life.1,2,4 Of note, our participants with moderate OA were able to complete tasks of daily 373 
living, albeit with greater pain and impaired mobility than controls. Despite pain, it is 374 
beneficial for knee OA patients to continue to move and load their joints to ensure that 375 
essential synovial fluid receives adequate nutrition and continues to provide appropriate 376 
lubrication, and to maintain muscle strength and aid in joint stability. Effective 377 
analgesics may help restore function and quality of life for patients with knee OA and 378 
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are considered appropriate according to Osteoarthritis Research Society International 379 
guidelines for non-surgical management of knee OA.35 380 
 381 
Due to the small sample size, this exploratory study has limited power and precision. 382 
For the kinetic data, sample sizes were particularly small due to missing data and paired 383 
analysis. Given the small size of both groups, and the fact that controls were matched to 384 
OA participants for age and BMI, our study populations may not be representative of OA 385 
and general populations. In addition, we did not control for knee instability which could 386 
be relevant as previous studies using motion analysis found that knee instability, as well 387 
as severity of OA, affected walking ability and gait.28,36 While we analyzed the primary 388 
3D motion outcomes separately for the OA-affected and the non-affected knee, the 389 
timed functional activities were analyzed by left or right leg despite heterogeneity as to 390 
which knee was affected among OA subjects. In addition, no adjustments were made 391 
for multiple comparisons. The researchers and subjects were not blinded to study group 392 
(OA or control). Lack of blinding of the researchers who were involved in the data 393 
collection should, therefore, be regarded as a limitation of the study.  394 
Due to the specificity of the inclusion criteria, we had to screen large numbers of people 395 
to recruit participants. A larger future study with greater statistical power would likely 396 
require recruitment from a wider geographical area and more extensive recruitment 397 
tools (eg, social media) to maintain these inclusion/exclusion criteria. 398 
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 399 
CONCLUSIONS 400 
Measures that involve some aspect of speed of task execution (particularly 401 
ascending/descending stairs, tying shoes, sitting/standing), hip and knee moments 402 
while walking, trunk ROM, and strides per minute while ascending and descending 403 
stairs are useful in discriminating OA patients from participants without knee pathology 404 
and can be considered as outcomes in future OA intervention trials. If 3D motion 405 
analysis variables are used, ascending/descending stairs better distinguishes OA 406 
patients from persons without knee pathology than does walking on a level surface. 407 
Timed functional tasks (10-meter walk, time to tie shoelaces, time to sit and stand) and 408 
cadence (steps per minute) measured with the ActivPAL device are also representative 409 
of everyday tasks. 410 
 411 
LIST OF ABBREVIATIONS 412 
AE, adverse event 413 
BMI, body mass index  414 
%BW, percent body weight 415 
EQ-5D, European Quality of Life–5 Dimensions 416 
EULAR, European League Against Rheumatism  417 
KOOS, Knee Injury and Osteoarthritis Outcome Score  418 
OA, osteoarthritis 419 
ROM, range of motion 420 
SD, standard deviation  421 
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FIGURE LEGENDS 570 
 571 
Figure 1. Cadence (steps per minute) Measured by ActivPAL in OA Participants 572 
(n=10) and Controls (n=8). This figure graphically shows a categorical analysis of 573 
cadence (spm) gathered from the ActivPAL for each group (OA and controls) on days 1 574 
and day 2. The different colors indicate the proportion of subjects in each cadence 575 
category, spanning a range of approximately 11 spm; dark blue indicates the slowest 576 
spm and red indicates the fastest. OA, osteoarthritis; spm, steps per minute. 577 
 578 
 579 
Figure 2. Percentage of OA Participants (n=10; blue) and Controls (n=7; red) 580 
Reporting “Some Problems” or “Extreme Problems” (Scores of 2 or 3) on the EQ-581 
5D Questionnaire. The 5 domains of the EQ-5D are each scored as 1=no problems; 582 
2=some problems; and 3=extreme problems.16 EQ-5D, European Quality of Life–5 583 
Dimensions; OA, osteoarthritis. 584 
 585 
 586 
  587 
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TABLES 588 
Table 1. Demographic Characteristics 589 
 OA Participants 
(n=10) 
Controls (n=8) P Valuea 
Age, mean (SD), 
years 
58.6 (6.02) 59.62 (3.85) 0.315 
Gender, n (%)    
Female 8 (80) 6 (75) — 
Male 2 (20) 2 (25) — 
Height, mean (SD), m 1.71 (0.089) 1.70 (0.12) 0.696 
Weight, mean (SD), 
kg 
91.52 (15.09) 87.58 (16.01) 0.573 
BMI, mean (SD), 
kg/m2 
30.82 (3.14) 29.80 (3.37) 0.315 
Numerical pain rating, 
mean (SD)b 
5.22 (0.97) Not applicable — 
aWilcoxon signed rank test. bNumeric pain rating scale from 0 (no pain) to 10 (highest 590 
pain). 591 
BMI, body mass index; OA, osteoarthritis; SD, standard deviation. 592 
 593 
 594 
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 595 
Table 2. Level Walking 3D Motion Analysis  596 
 Mean (SD), Degrees Mean (SD), Degrees 
 OA-Affected 
Limb (n=8) 
Matched 
Control Limb 
(n=8) 
P Valuea OA-Unaffected 
Limb (n=8) 
Matched 
Control Limb 
(n=8)
P Valuea 
Hip moment       
Max sagittal 
(flexion [+ve]) 
4.83 
(1.72) 
4.94 
(1.77) 
1.000 4.00 
(1.62) 
4.65 
(1.72) 
0.575 
Max frontal 
(adduction [+ve]) 
4.92 
(1.32) 
6.20 
(0.92) 
0.036b 5.06 
(1.64) 
5.51 
(1.20) 
0.263 
 
Max transverse 
(internal rotation 
[+ve]) 
0.63 
(0.39) 
0.67 
(0.36) 
0.674 0.78 
(0.34) 
0.52 
(0.15) 
0.161 
Min sagittal 
(flexion [+ve]) 
−5.02 
(2.30) 
−4.90 
(1.09) 
1.000 −5.61 
(2.14) 
−4.40 
(1.30) 
0.123 
Min frontal 
(adduction [+ve]) 
−1.23 
(0.86) 
−0.70 
(0.23) 
0.069 −1.46 
(1.18) 
−1.10 
(0.34) 
0.327 
Min transverse  
(internal rotation 
[+ve]) 
−0.64 
(0.51) 
−1.18 
(0.25) 
0.069 −0.72 
(0.30) 
−0.99 
(0.48) 
0.327 
Knee moment        
Max sagittal 
(flexion [+ve]) 
2.59 
(1.20) 
5.00 
(1.11) 
0.025b 3.39 
(0.77) 
4.36 
(0.70) 
0.069 
Max frontal 
(adduction [+ve]) 
2.30 
(1.39) 
2.75 
(0.72) 
0.674 1.98 
(0.95) 
2.11 
(0.38) 
0.674 
Max transverse 
(internal rotation 
[+ve]) 
0.69 
(0.40) 
0.82 
(0.21) 
0.327 0.67 
(0.32) 
0.63 
(0.19) 
1.000 
Min sagittal −2.45 −1.73 0.123 −2.33 −1.70 0.208 
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(flexion [+ve]) (0.56) (0.98)  (0.68) (0.82) 
Min frontal 
(adduction [+ve]) 
−0.68 
(0.15) 
−0.58 
(0.26) 
0.327 −0.73 
(0.26) 
−0.82 
(0.26) 
0.575 
Min transverse 
(internal rotation 
[+ve]) 
−0.15 
(0.10) 
−0.28 
(0.16) 
0.327 −0.16 
(0.09) 
−0.22 
(0.08) 
0.484 
Ankle moment        
Max sagittal 
(dorsiflexion [+ve]) 
7.96 
(1.00) 
8.65 
(1.23) 
0.161 8.41 
(0.88) 
8.22 
(0.95) 
0.674 
Max frontal 
(inversion [+ve]) 
0.23 
(0.11) 
0.51 
(0.30) 
0.069 0.33 
(0.19) 
0.44 
(0.29) 
0.484 
Max transverse 
(internal rotation 
[+ve]) 
1.47 
(0.53) 
1.69 
(0.42) 
0.401 1.45 
(0.39) 
1.66 
(0.52) 
0.484 
Min sagittal 
(dorsiflexion [+ve]) 
−1.01 
(0.21) 
−0.99 
(0.27) 
0.779 −0.24 
(0.67) 
−0.24 
(0.87) 
1.000 
Min frontal 
(inversion [+ve]) 
−0.80 
(0.25) 
−0.52 
(0.15) 
0.093 −0.12 
(0.28) 
−0.12 
(0.32) 
0.779 
Min transverse 
(internal rotation 
[+ve]) 
−0.20 
(0.12) 
−0.22 
(0.11) 
0.889 0.01 
(0.20) 
0.02 
(0.15) 
0.575 
Joint moments (%BW*h) (sagittal, frontal, transverse planes) for affected and unaffected limbs of OA participants 597 
compared with participants without knee pathology are shown. 598 
aWilcoxon signed rank test. bDenotes statistically significant difference (P<0.05).  599 
%BW*h, percent body weight x height; Min, minimum; Max, maximum; OA, osteoarthritis; SD, standard deviation. 600 
 601 
 602 
 603 
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Table 3. Ascending and Descending Stairs, Temporal Data from 3D Motion Analysis 604 
 605 
 Mean (SD)  Mean (SD)  
 OA-Affected 
Limb (n=8) 
Matched 
Control Limb 
(n=8) 
P Valuea OA-
Unaffected 
Limb (n=8) 
Matched 
Control Limb 
(n=8) 
P Valuea 
Ascending stairs 
Speed, m/s 0.31 
(0.06) 
0.33 
(0.06) 
0.025b 0.31 
(0.06) 
0.33 
(0.06) 
0.025b 
Stride length, m 0.45 
(0.13) 
0.39 
(0.02) 
0.069 0.52 
(0.13) 
0.39 
(0.02) 
0.067 
Cycle time, s 1.60 
(0.36) 
1.22 
(0.18) 
0.025b 1.65 
(0.41) 
1.22 
(0.18) 
0.049b 
Stance time, s 1.12 
(0.25) 
0.84 
(0.15) 
0.036b 1.18 
(0.38) 
0.84 
(0.15) 
0.049b 
Swing time, s 0.48 
(0.14) 
0.37 
(0.05) 
0.036b 0.47 
(0.12) 
0.37 
(0.05) 
0.207 
Strides per 
minute 
35.32 
(5.34) 
44.43 
(6.32) 
0.036b 36.65 
(6.30) 
43.06 
(5.48) 
0.049b 
Descending stairs 
Speed, m/s 0.31 
(0.06) 
0.33 
(0.07) 
0.208 0.31 
(0.06) 
0.33 
(0.07) 
0.208 
Stride length, m 0.33 
(0.06) 
0.45 
(0.13) 
0.735 1.29 
(0.12) 
0.52 
(0.13) 
0.025b 
Cycle time, s 0.39 
(0.02) 
1.60 
(0.36) 
0.063 0.40 
(0.04) 
1.64 
(0.41) 
0.036b 
Stance time, s 1.22 
(0.18) 
1.12 
(0.25) 
0.063 1.21 
(0.17) 
1.17 
(0.38) 
0.036b 
Swing time, s 0.84 
(0.15) 
0.48 
(0.14) 
0.271 0.84 
(0.17) 
0.47 
(0.12) 
0.123 
Strides per 
minute 
39.40 
(8.93) 
50.23 
(6.98) 
0.043b 38.80 
(10.12) 
50.30 
(6.73) 
0.036b 
aWilcoxon signed rank test. bDenotes statistically significant difference (P<0.05). 606 
m, meters; m/s meters per second; OA, osteoarthritis; s, seconds; SD, standard deviation. 607 
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 609 
 610 
Table 4. Ascending and Descending Stairs, Joint Range of Motion on 3D Motion Analysis 611 
 612 
 Mean (SD), Degrees Mean (SD), Degrees 
 OA-Affected 
Limb (n=8) 
 Matched 
Control Limb 
(n=8) 
P Valuea OA-
Unaffected 
Limb (n=8)  
Matched 
Control Limb 
(n=8) 
P Valuea 
While ascending stairs 
Hip ROM       
Sagittal 23.85 
(4.73) 
21.85 
(3.40) 
0.575 23.44 
(4.28) 
21.19 
(3.52) 
0.484 
Frontal 14.52 
(7.83) 
10.79 
(3.70) 
0.093 15.13 
(4.25) 
11.52 
(3.01) 
0.889 
Transverse 17.45 
(5.39) 
13.51 
(3.42) 
0.484 17.00 
(4.51) 
12.07 
(2.54) 
0.327 
Knee ROM       
Sagittal 68.70 
(14.80) 
75.46 
(4.90) 
0.401 77.40 
(6.73) 
76.27 
(5.67) 
0.327 
Frontal 14.63 
(5.23) 
8.49 
(1.35) 
0.208 16.43 
(5.29) 
8.18 
(2.47) 
0.049b 
Transverse 14.19 
(3.76) 
14.75 
(2.36) 
0.263 17.21 
(2.25) 
12.96 
(3.35) 
0.263 
Ankle ROM       
Sagittal 50.65 
(8.58) 
51.45 
(6.97) 
0.049b 52.53 
(8.95) 
48.05 
(5.65) 
0.069 
Frontal 14.82 
(4.62) 
14.90 
(1.67) 
0.575 17.19 
(5.90) 
15.07 
(2.67) 
0.779 
Transverse 13.60 
(5.50) 
13.49 
(5.99) 
0.401 13.16 
(3.01) 
11.00 
(3.00) 
0.327 
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Trunk ROM       
Sagittal 5.69 
(1.22) 
4.53 
(1.00) 
0.017b 6.38 
(1.46) 
4.29 
(0.95) 
0.036b 
Frontal 7.98 
(3.60) 
5.15 
(2.50) 
0.069 6.42 
(2.71) 
5.69 
(1.48) 
0.161 
Transverse 20.26 
(7.96) 
13.04 
(1.86) 
0.036b 22.26 
(11.33) 
11.94 
(2.60) 
0.017b 
While descending stairs 
Hip ROM       
Sagittal 13.50 
(5.99) 
23.86 
(4.73) 
0.327 21.20 
(3.52) 
23.44 
(4.28) 
0.069 
Frontal 21.85 
(3.40) 
14.53 
(7.83) 
0.327 11.03 
(3.00) 
15.13 
(4.25) 
0.263 
Transverse 10.80 
(3.70) 
17.45 
(5.39) 
0.161 11.52 
(3.01) 
16.99 
(4.51) 
0.123 
Knee ROM       
Sagittal 13.51 
(3.42) 
68.70 
(14.80) 
0.263 76.27 
(5.67) 
77.39 
(6.73) 
0.208 
Frontal 75.47 
(4.90) 
14.63 
(5.23) 
0.025b 12.08 
(2.54) 
16.44 
(5.03) 
0.123 
Transverse 8.49 
(1.35) 
14.20 
(3.76) 
0.327 8.18 
(2.47) 
17.21 
(2.25) 
0.036b 
Ankle ROM       
Sagittal 13.04 
(1.86) 
50.66 
(8.58) 
0.889 11.95 
(2.60) 
52.53 
(8.95) 
0.069 
Frontal 51.46 
(6.97) 
14.82 
(4.62) 
0.889 48.05 
(5.65) 
17.20 
(5.90) 
0.263 
Transverse 14.89 
(1.67) 
13.65 
(5.50) 
1.000 15.07 
(2.67) 
13.16 
(3.01) 
0.123 
Trunk ROM       
Sagittal 50.23 5.69 0.069 50.30 6.38 0.017b 
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(6.98) (1.22) (6.74) (1.46) 
Frontal 4.53 
(1.00) 
7.98 
(3.60) 
0.263 4.29 
(0.95) 
6.42 
(2.71) 
0.889 
Transverse 5.15 
(2.50) 
20.27 
(7.96) 
0.025b 5.70 
(1.48) 
22.27 
(11.33) 
0.049b 
aWilcoxon signed rank test. bDenotes statistically significant difference (P<0.05).  613 
OA, osteoarthritis; ROM, range of motion; SD, standard deviation. 614 
 615 
Table 5. Time to Complete Functional Tests 616 
 617 
Functional Test Mean (SD) Time to Complete Test, Seconds P Valuea 
OA Group (n=10) Controls (n=8) 
Timed 10-meter walk 9.63 (2.17) 7.54 (1.01) 0.034b 
Tying shoelaces    
Right leg 17.32 (5.95) 10.31 (4.00) 0.009b 
Left leg 17.37 (7.56) 10.71 (4.40) 0.043b 
Sit to stand    
Right leg 3.10 (2.07) 1.57 (0.31) 0.002b 
Left leg 2.91 (2.03) 1.49 (0.29) 0.001b 
Stand to sit    
Right leg 2.95 (1.69) 1.74 (0.44) 0.027b 
Left leg 3.13 (2.13) 1.67 (0.34) 0.012b 
aWilcoxon signed rank test. bDenotes statistically significant difference (P<0.05) for participants with OA vs healthy 618 
participants. 619 
OA, osteoarthritis; SD, standard deviation. 620 
 621 
 622 
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Table 6. Patient-Reported Outcome Measures of Pain and Function 623 
Outcomes Scale OA Group (n=10) Controls (n=7) P Valuea 
KOOS, mean (SD) scoreb    
Pain 54.18 (12.78) 95.57 (11.7) <0.005c 
Symptoms 52.85 (18.34) 95.85 (6.69) <0.005c 
Activities of daily living 63.40 (18.05) 99.14 (2.26) <0.005c 
Sports/recreation 32.63 (14.18) 97.00 (5.74) <0.005c 
Quality of life 31.89 (19.42) 93.85 (13.78) <0.005c 
WOMAC, mean (SD) scored    
Knee stiffness 1.75 (0.754) 0.214 (0.393) <0.005c 
Knee pain 1.50 (0.707) 0.075 (0.212) <0.005c 
Function 1.49 (0.72) 0.329 (0.086) <0.005c 
Total 1.51 (0.71) 0.486 (0.111) <0.005c 
aWilcoxon signed rank test. 624 
bIndividual items on the KOOS are each rated on a 5-point Likert scale; summed scores for each of the 5 dimensions of 625 
the scale are transformed to a percentage score from 0 (extreme knee problems) to 100 (no knee problems).11 626 
cDenotes statistically significant difference (P<0.05) for participants with OA vs healthy participants. 627 
dIndividual items on the WOMAC are rated on a 5-point Likert scale (0=none to 4=extreme), and scores for each of the 3 628 
dimensions are summed and then divided by the number of items in that dimension; the total score is obtained by 629 
summing the scores for all 26 items (7 for pain, 2 for stiffness, and 17 for physical function) and dividing by 26.17 630 
KOOS, Knee Injury and Osteoarthritis Outcome Score; OA, osteoarthritis; SD, standard deviation; WOMAC, Western 631 
Ontario McMaster Universities Osteoarthritis Index. 632 
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